Dominican Republic Meropenem Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF DOMINICAN REPUBLIC MEROPENEM MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7 MULTIVARIATE MODELLING

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END-USER COVERAGE GRID

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSIS

4.2 PORTER'S FIVE FORCES ANALYSIS

4.3 MARKET ACCESS

4.3.1 REGULATORY ENTRY PATHWAYS

4.3.2 PUBLIC HEALTH INSURANCE AND REIMBURSEMENT MECHANISMS

4.3.3 PRICING AND PROCUREMENT POLICIES

4.3.4 DISTRIBUTION AND SUPPLY CHAIN FRAMEWORK

4.3.5 HEALTH TECHNOLOGY ASSESSMENT AND INCLUSION CRITERIA

4.3.6 PRIVATE INSURANCE AND OUT-OF-POCKET MARKET

4.3.7 STEWARDSHIP, SURVEILLANCE, AND ACCESS TENSIONS

4.3.8 CONCLUSION

4.4 PIPELINE ANALYSIS

5 REGULATION COVERAGE — DOMINICAN REPUBLIC MEROPENEM MARKET

5.1 PRODUCT CODES

5.2 CERTIFIED STANDARDS

5.3 SAFETY STANDARDS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING CLINICAL NEED DUE TO INCREASED SEVERE INFECTIONS AND CARBAPENEM USE

6.1.2 GROWING ANTIMICROBIAL RESISTANCE (AMR) TO OTHER BETA-LACTAMS

6.1.3 HOSPITAL-CENTERED DEMAND OF MEROPENEM

6.2 RESTRAINTS

6.2.1 REGULATORY/IMPORT BARRIERS AND REGISTRATION REQUIREMENTS

6.2.2 COMPETITION FROM GENERICS AND OTHER CARBAPENEMS

6.3 OPPORTUNITIES

6.3.1 SUPPLY CONTRACTS WITH PUBLIC HOSPITALS AND CENTRALIZED TENDERS

6.3.2 LOCAL DISTRIBUTION PARTNERSHIPS

6.4 CHALLENGES

6.4.1 RISING CARBAPENEM RESISTANCE REDUCES LONG-TERM CLINICAL UTILITY

6.4.2 PRICE SENSITIVITY & BUDGET CONSTRAINTS FOR PEOPLE

7 DOMINICAN REPUBLIC MEROPENEM MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 MEROPENEM TRIHYDRATE

7.3 MEROPENEM SODIUM

8 DOMINICAN REPUBLIC MEROPENEM MARKET, BY DOSE

8.1 OVERVIEW

8.2 1 GM/VIAL

8.3 500 MG/VIAL

9 DOMINICAN REPUBLIC MEROPENEM MARKET, BY PATIENT TYPE

9.1 OVERVIEW

9.2 ADULT

9.3 CHILDREN

10 DOMINICAN REPUBLIC MEROPENEM MARKET, BY APPLICATION

10.1 OVERVIEW

10.2 NOSOCOMIAL INFECTION

10.3 INTRA-ABDOMINAL INFECTION

10.4 SKIN AND SKIN STRUCTURE INFECTION

10.5 MENINGITIS

10.6 OTHERS

11 DOMINICAN REPUBLIC MEROPENEM MARKET, BY END-USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 CLINICS

11.4 RESEARCH & ACADEMIC INSTITUTES

11.5 OTHERS

12 DOMINICAN REPUBLIC MEROPENEM MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 HOSPITAL PHARMACIES

12.3 RETAIL PHARMACIES

12.4 ONLINE PHARMACIES

13 DOMINICAN REPUBLIC DIABETES MARKET, COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: DOMINICAN REPUBLIC

14 SWOT ANALYSIS

15 COMPANY PROFILES

15.1 PFIZER INC

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUE ANALYSIS

15.1.3 PRODUCT PORTFOLIO

15.1.4 RECENT DEVELOPMENT

15.2 SANDOZ INC.

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 PRODUCT/ SERVICE PORTFOLIO

15.2.4 RECENT DEVELOPMENT

15.3 LUPIN

15.3.1 COMPANY SNAPSHOT

15.3.2 REVENUE ANALYSIS

15.3.3 PRODUCT PORTFOLIO

15.3.4 RECENT DEVELOPMENT

15.4 B. BRAUN SE

15.4.1 COMPANY SNAPSHOT

15.4.2 REVENUE ANALYSIS

15.4.3 PRODUCT/ SERVICE PORTFOLIO

15.4.4 RECENT DEVELOPMENT

15.5 CIPLA

15.5.1 COMPANY SNAPSHOT

15.5.2 REVENUE ANALYSIS

15.5.3 PRODUCT PORTFOLIO

15.5.4 RECENT DEVELOPMENT

15.6 AETOS PHARMA PRIVATE LIMITED

15.6.1 COMPANY SNAPSHOT

15.6.2 PRODUCT PORTFOLIO

15.6.3 RECENT DEVELOPMENT

15.7 EUGIA US

15.7.1 COMPANY SNAPSHOT

15.7.2 PRODUCT PORTFOLIO

15.7.3 RECENT DEVELOPMENT

15.8 FRESENIUS SE & CO. KGAA

15.8.1 COMPANY SNAPSHOT

15.8.2 REVENUE ANALYSIS

15.8.3 PRODUCT/ SERVICE PORTFOLIO

15.8.4 RECENT DEVELOPMENTS

15.9 IND-SWIFT LABORATORIES LTD.

15.9.1 COMPANY SNAPSHOT

15.9.2 REVENUE ANALYSIS

15.9.3 PRODUCT PORTFOLIO

15.9.4 RECENT DEVELOPMENT

15.1 JANAXA PHARMACEUTICALS

15.10.1 COMPANY SNAPSHOT

15.10.2 PRODUCT PORTFOLIO

15.10.3 RECENT DEVELOPMENT

15.11 LIVEALTH

15.11.1 COMPANY SNAPSHOT

15.11.2 PRODUCT PORTFOLIO

15.11.3 RECENT DEVELOPMENT

15.12 MACLEODS PHARMACEUTICALS LTD.

15.12.1 COMPANY SNAPSHOT

15.12.2 PRODUCT PORTFOLIO

15.12.3 RECENT DEVELOPMENT

15.13 SANOFI

15.13.1 COMPANY SNAPSHOT

15.13.2 REVENUE ANALYSIS

15.13.3 PRODUCT PORTFOLIO

15.13.4 RECENT DEVELOPMENT

15.14 SALIUS PHARMA PVT. LTD

15.14.1 COMPANY SNAPSHOT

15.14.2 PRODUCT PORTFOLIO

15.14.3 RECENT DEVELOPMENT

15.15 TAJ PHARMACEUTICALS LIMITED

15.15.1 COMPANY SNAPSHOT

15.15.2 PRODUCT PORTFOLIO

15.15.3 RECENT DEVELOPMENT

15.16 VENUS REMEDIES LTD

15.16.1 COMPANY SNAPSHOT

15.16.2 REVENUE ANALYSIS

15.16.3 PRODUCT PORTFOLIO

15.16.4 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS